[HTML][HTML] Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis …
Abstract Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …
[HTML][HTML] Navigating the rapidly evolving advanced urothelial carcinoma treatment landscape: insights from Italian experts
Abstract Purpose of Review To discuss recent advances in the treatment of advanced
urothelial carcinoma (UC) and how best to incorporate new therapies into clinical practice …
urothelial carcinoma (UC) and how best to incorporate new therapies into clinical practice …
[HTML][HTML] Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers
Summary The US Food and Drug Administration (FDA) approval of the selective RET
inhibitors selpercatinib and pralsetinib has led to a paradigm change in the treatment of RET …
inhibitors selpercatinib and pralsetinib has led to a paradigm change in the treatment of RET …
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a …
WP Yong, FSW Teo, LLS Teo, MCH Ng… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Interstitial lung disease (ILD) or pneumonitis remains an important adverse
event identified with treatment with antibody–drug conjugates (ADCs). Drug-induced ILD …
event identified with treatment with antibody–drug conjugates (ADCs). Drug-induced ILD …
Alpelisib induced interstitial lung disease in a patient with advanced breast cancer
A Isiklar, G Basaran, B Sepin… - Journal of Oncology …, 2023 - journals.sagepub.com
Background Interstitial lung disease interstitial lung disease is a group of respiratory
diseases that causes progressive fibrosis. Many of the recently approved oncology drugs …
diseases that causes progressive fibrosis. Many of the recently approved oncology drugs …
COVID-19 as a Primer for Drug-Induced Pneumonitis in Patients With Cancer.
A Yenamandra, A Greidinger… - Journal of …, 2023 - search.ebscohost.com
BACKGROUND: Drug-related pneumonitis is a hallmark adverse event of some systemic
antican-cer therapies and is characterized by chronic lung inflammation that requires …
antican-cer therapies and is characterized by chronic lung inflammation that requires …
[PDF][PDF] ЛЕКАРСТВЕННО-ИНДУЦИРОВАННЫЕ НЕИНФЕКЦИОННЫЕ ПОРАЖЕНИЯ ЛЕГКИХ У ПАЦИЕНТОВ С ОПУХОЛЕВЫМИ ЗАБОЛЕВАНИЯМИ СИСТЕМЫ …
ВИ Трофимов, ИС Моисеев - 1spbgmu.ru
Онкологические заболевания являются значимой проблемой в современном мире,
поскольку затрагивают все слои населения и различные возрастные группы как в …
поскольку затрагивают все слои населения и различные возрастные группы как в …
[HTML][HTML] La gestione delle tossicità polmonari indotte dalla terapia target e dalla immunoterapia nel carcinoma polmonare: ruolo dello pneumologo
V Bonti, K Ferrari - Rassegna di Patologia dell'Apparato …, 2021 - aiporassegna.it
Il tumore del polmone rappresenta la principale causa di morte per neoplasia nel mondo.
Negli ultimi anni, la miglior conoscenza dei driver molecolari alla base dello sviluppo del …
Negli ultimi anni, la miglior conoscenza dei driver molecolari alla base dello sviluppo del …